Open AccessCOMBINATION EFFECT OF LULICONAZOLE AND CLOBETASOL FOR TREATMENT OF SKIN AILMENTS
Author(s) -
DEEPAK PRASHAR,
Vivek Kumar,
KHUSHBOO JASRA
Publication year - 2022
Publication title -
international journal of current pharmaceutical research
Language(s) - English
Resource type - Journals
ISSN - 0975-7066
DOI - 10.22159/ijcpr.2022v14i2.1949
Subject(s) - clobetasol propionate , detection limit , reproducibility , propionate , absorbance , medicine , chromatography , dermatology , chemistry , biochemistry , psoriasis
Objective: The new combination for Luliconazole and Clobetasol Propionate was approved for the treatment of a variety of skin disease. The main objective of this research is development and validation of novel, simple, fast and responsive derivative spectroscopic process for simultaneous estimation of newly approved combination Luliconazole (LLZ) and Clobetasol Propionate (CLP).
Methods: Here in this first derivative spectroscopic method, the absorbance of LLZ and CLP was taken at 312 nm (ZCP of CLP) and 249 nm (ZCP of LLZ), respectively. Establishment of linearity was in a concentration varies from 10-50 µg/ml for Luliconazole and 5-25µg/ml for Clobetasole Propionate.
Results: From the method developed above the R2 value observed for LLZ and CLP is 0.9961. Statistical validation of accuracy and reproducibility was done for planned procedure with the help of recovery studies. The mean % recovery of Luliconazole and Clobetasol Propionate was found to be 99.45 % and 99.43%, respectively. For LLZ the Limit of detection is 0.9988 µg/ml and limit of quantification is 0.0009µg/ml and for CLP the Limit of detection is0.0164µg/ml and limit of quantification 0.0027µg/ml.
Conclusion: From research work the method development was done and shows fast, precise, exact and easy accessible laboratory procedure for routine evaluation of combination drugs.